Search bioRxiv⌕ Search

Biology subjects

Rosenbluth, J. M.

Publications and source records attributed to Rosenbluth, J. M..

4 recordsLinked to original sources

AutoBlot: deterministic single-cell western blotting reveals proteomic diversity in rare cell populations

Protein abundance and proteoform composition are direct determinants of cellular phenotype, yet both remain difficult to quantify in individual cells from specimens available in limited numbers. Single-cell western blotting (scWB) provides quantitative, molecular-mass-resolved protein measurements but relies on Poisson-limited gravity settling, requiring approximately 10 starting cells while constraining single-cell microwell occupancy to a theoretical maximum of 36.8%. Here, we introduce AutoBlot, an image-guided piezoelectric dispensing approach that deterministically loads individual cells into predefined scWB microwells. AutoBlot achieved approximately 98% single-cell occupancy among targeted microwells while operating from as few as 10,000 starting cells. Across the tested cell concentrations, measured occupancy exceeded Poisson predictions by 31- to 904-fold, and the same dispensing strategy enabled deterministic cell-bead co-loading. We applied AutoBlot to 1,449 cells from seven patient-derived breast organoids generated from histologically normal mammary tissue. Measurements of five lineage-associated proteins revealed donor-to-donor variation, differences associated with germline BRCA1 and menopausal status, and discordance between surface-marker- and cytokeratin-based lineage assignments. AutoBlot also resolved ER-immunoreactive species at approximately 66 and 46 kDa in individual PDO cells. These results establish deterministic cell loading as a strategy for extending molecular-mass-resolved single-cell protein analysis to heterogeneous, cell-limited specimens.

bioengineering↗

Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapies

Poor therapeutic response in subsets of breast cancer (BC) patients poses an ongoing challenge. Here, we present a biomarker-guided characterization of 44 patient-derived BC organoids, with the aim of modeling resistant disease with greater fidelity and developing an in-vitro system grounded in clinical data for testing alternative treatment strategies. We utilized patient transcriptomic and outcome data from the I-SPY2 clinical trial to develop predictive models of response to a range of therapies, using only organoid-detectable biomarkers as input. A model predicting response to veliparib-platinum chemotherapy (VP) in triple-negative BC (TNBC) was validated in organoids, showing that in vitro drug responses matched predictions from the patient data-derived model. A drug screen in VP-resistant TNBC organoids identified combination treatments that overcame resistance to cisplatin, including pro-apoptotic therapies. This demonstrates that gene expression-based resistance models derived from patient data can be successfully modeled in organoids that can then be used for therapeutic evaluation.

cancer biology↗

Fine needle aspiration biopsy of breast specimens effectively harvests cells for patient-derived organoids modeling breast ductal carcinoma in situ

BackgroundPatient-derived organoids (PDOs) generated from benign breast tissue and breast carcinomas have successfully recapitulated their respective in vivo counterparts. PDOs model tumorigenesis and allow for screening of novel therapeutics personalized to individual patients. However, acquiring cells to generate PDOs is cumbersome. We demonstrate the feasibility of fine needle aspiration biopsy (FNAB) for harvesting cells for PDOs modeling ductal carcinoma in situ (DCIS). MethodsSurgical specimens from patients with biopsy-proven DCIS were used for this study. Core needle biopsy (CNB) was performed on fresh specimens in the operating room, and tissue was mechanically dissociated before culture in basement membrane extract (BME) and organoid medium to generate PDOs. FNAB was performed in the gross room on fresh specimens, and the remaining aspirate was similarly submitted for PDO culture. ResultsPDOs were successfully generated in 15/18 specimens obtained by CNB and 7/11 specimens obtained by FNAB. The average time to initial organoid growth was 4 days for FNAB specimens compared to 19.3 days for CNB specimens. Tumor cells were seen on 7/11 FNAB smears and 16/18 CNB touch preps. Immunofluorescence staining confirmed the presence of both luminal and myoepithelial cells in derived PDOs. ConclusionsFNAB effectively obtains cells for PDOs modeling DCIS. CNB after mincing yielded PDOs with a high success rate, but they were slow to establish. Notably, the time to organoid growth was significantly shorter for FNAB specimens. Thus, FNAB offers an efficient alternative for breast PDO culture and can reduce the time and resources spent on generating PDO cultures.

cell biology↗

Implantation of engineered adipocytes that outcompete tumors for resources suppresses cancer progression

Tumors acquire an increased ability to obtain and metabolize nutrients. Here, we engineered and implanted adipocytes to outcompete tumors for nutrients and show that they can substantially reduce cancer progression. Growing cells or xenografts from several cancers (breast, colon, pancreas, prostate) alongside engineered human adipocytes or adipose organoids significantly suppresses cancer progression and reduces hypoxia and angiogenesis. Transplanting modulated adipocyte organoids in pancreatic or breast cancer mouse models nearby or distal from the tumor significantly suppresses its growth. To further showcase therapeutic potential, we demonstrate that co-culturing tumor organoids derived from human breast cancers with engineered patient-derived adipocytes significantly reduces cancer growth. Combined, our results introduce a novel cancer therapeutic approach, termed adipose modulation transplantation (AMT), that can be utilized for a broad range of cancers.

cancer biology↗